Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16051464 | 0.98 | THRA (0.65) | THRAHPGDLMNAAR | |
| SCHEMBL8231736 | 0.94 | THRA (0.59) | THRAHPGDLMNAAR | |
| SCHEMBL9489980 | 0.87 | HPGD (0.57) | THRAHPGDLMNA | |
| SCHEMBL3558724 | 0.87 | LMNA (0.56) | THRAHPGDLMNAAR | |
| SCHEMBL3563414 | 0.84 | AR (0.62) | LMNAARTP53TSHR | |
| SCHEMBL9425268 | 0.84 | THRA (0.62) | THRAHPGDLMNAAR | |
| SCHEMBL27846668 | 0.83 | WDR5 (0.53) | — | |
| SCHEMBL8364601 | 0.83 | LMNA (0.57) | THRAHPGDLMNAARTP53 | |
| SCHEMBL10886886 | 0.83 | LMNA (0.57) | THRAHPGDLMNAARTP53 | |
| SCHEMBL8361838 | 0.83 | LMNA (0.57) | THRAHPGDLMNAARTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102395270-B | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same | FASGEN INC | 2014-11-12 | — | — | CN | disclosed |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| CN-102395270-A | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same | FASGEN INC | 2012-03-28 | — | — | CN | disclosed |
| EP-2303013-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | Fasgen, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010005922-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | FASGEN, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | THRA 4731/4885HPGD 1419/4885LMNA 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.